Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Yet another cohort underway…for Pelareorep

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Dec 03, 2024 5:17pm

97 Views

Post# 36343880

RE:RE:Yet another cohort underway…for Pelareorep

Note.... Wow! I'm sure many here are wondering how you came to that conclusion?
If anything, I thought it was a tag team partnership
I'm sure I will get lambasted for that.
I was categorized as a basher by you?
Based upon that diagnosis, your analysis and or conclusion should be taken with a grain of pessimism
Fire away now but I will not reply either.

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?